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at the National Institute of Health, the FDA, and the Physician's Desk Reference 
versions 1980-2012. Data were collected by 2 researchers and the MOAs classified 
as: known, unknown, or hypothesized. Another investigator resolved observed 
differences. Chi-square was used to assess differences in proportions. RESULTS: 
A total of 816 new drugs (79 BLA and 737 NMEs) were approved by the FDA 
during the study period. The MOA was known for 95.7% of biologics and 64.4%  
of NMEs. Nervous system was the Anatomical Therapeutic Chemical class  
with the lowest proportion of known MOA (11.8% known MOA out of 77 approved 
products). Blood and blood forming organs was the class with the highest 
proportion of known MOAs (92.7%; n=89). The proportion of products  
with known MOA increased overtime from 56.4% (n=202 approvals) in the 1980s 
to 71.7% (n=265) in the 2000s. No significant differences were observed in  
terms of known MOA between orphan/non-orphan drugs, 
marketed/discontinued products, and safety withdrawals. CONCLUSIONS: An 
important number of drugs did not have a known MOA. In addition, there was 
great variability in the wording of MOA, especially hypothetical ones. The lack of 
information about MOA could result in safety and efficacy problems. FDA should 
consider standardizing the label with regard to MOA and encourage 
manufacturers to continue collecting evidence to verify a drug’s MOA after 
market approval.  
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OBJECTIVES: Recent events in Europe and the US have brought into question the 
effectiveness of existing regulatory frameworks to ensure the performance, 
safety, and quality of new medical devices. Given that policymakers are 
currently exploring ways to reform medical device regulation to address these 
issues, this study aimed to examine current medical device regulation policies in 
both jurisdictions, understand outstanding regulatory challenges, and identify 
ways to improve regulatory practices. METHODS: The study examined the 
respective regulatory systems based on a critical review of available, relevant 
scientific and grey literature. In addition, the websites of national medical device 
regulatory agencies (e.g., FDA) were reviewed for key legislative and policy 
documents. RESULTS: The review highlighted a number of challenges for 
medical device regulation in both jurisdictions: 1) finding the right balance 
between centralized and decentralized regulation; 2) ensuring sufficient 
evidence requirements to safeguard public health and certify performance, 
especially for high-risk devices; 3) implementing mechanisms and incentives for 
monitoring and evaluating post-market device safety and effectiveness; and, 4) 
providing adequate and transparent information exchange on the benefits and 
risks of new technologies. To address these issues, European and US policy 
makers and other stakeholders have implemented various initiatives or are 
considering their introduction. Specific policies include establishing a more 
centralized system of regulation in Europe; requiring uniform oversight and 
evidence requirements across and within European countries; and, use of 
national and European databases to track and monitor medical devices as well as 
registries to collect post-market data on effectiveness and safety. 
CONCLUSIONS: Additional actions are needed to ensure high-performing 
medical device regulation. These include providing sufficient incentives for 
manufacturers to conduct pre-market clinical studies, making market access 
conditional on rigorous post-marketing studies when available evidence is 
absent or limited, promoting international registry coordination, and bolstering 
information on the evidentiary basis for granting CE marks in Europe.  
 
PHP36  
PRIORITIZATION OF IN VITRO DIAGNOSTIC TESTS FOR UPDATING HEALTH 
COVERAGE IN COLOMBIA  
Diaz-Sotelo OD1, Barbosa Castro T2, Alfonso-Cristancho R3, Gallego G4 
1RANDOM Foundation, Bogota, DC, Colombia, 2RANDOM Foundation, Bogota DC, Colombia, 
3University of Washington, Seattle, WA, USA, 4University of Western Sydney, Sydney, Australia  
OBJECTIVES: In-vitro diagnostics (IVD) are essential for diagnosis, screening and 
monitoring diseases. IVD’s are emerging everyday but usually at a higher cost. 
Consequently, a formal health technology assessment (HTA) process to should 
determine its value. The prioritization to initiate this process is key given the 
limited resources available for HTA in developing countries. Our aim was to 
establish the prioritization and ranking of IVD’s for assessment for inclusion or 
ratification in the Colombian health care system. METHODS: Using an adapted 
prioritization tool from the MoH which included 13 standardized criteria grouped 
into four domains: population needs, benefits and risks of testing, policy 
priorities and system costs; we performed two rounds of surveys using online 
Delphi panels with 64 clinician of the 12 medical specialties pertinent to the 87 
IVD’s. The list of IVD’s selected was independently submitted by the National 
manufacturers association (ANDI). Prioritization and ranking were determined 
by preference weights and Pareto diagrams. RESULTS: From the 87 IVD tests 
evaluated, 55 were favorably scored and ranked; the remaining 32 IVD’s were not 
included in the ranking due to low favorability or lack of information. Highly 
specialized IVD tests with limited use in subspecialties or for rare conditions 
were often excluded. Tests evaluated with the highest favorability and ranked in 
the top quartile were often driven by conditions with high impact on the 
population which often coincides with policy priorities of the MoH. Costs and 
benefit-risk ratios seem less relevant. CONCLUSIONS: The use of this 
methodology, for the first time in Latin America in IVD’s, that integrates expert 
opinion and standardized criteria for prioritizing and ranking IVD’s to be 
considered for HTA is feasible and useful. Stakeholder involvement in 
prioritization and ranking technologies for HTA is particularly important in 
countries with limited resources to perform HTA for health care budget 
allocations.  
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OBJECTIVES: This research investigates the relationship between income, age, 
and the utilization of prescription drugs to determine variation by income levels 
and age group. METHODS: Data derived from a random sample of approximately 
6 million commercially insured members whose pharmacy benefits are managed 
by a large pharmacy benefit manager were used. The sample included all 
adjudicated claims and basic demographic information for the period 2010-2012 
combined with median income data at the Zip Code level based on Zip Code 
Tabulation Area data from the US Census Bureau (Five Year Sample of the 
American Community Survey). The outcome measure was annual average days’ 
supply of prescription medications. Least Squares Means Estimates of annual 
days supply by income decile were adjusted by member age group. Median 
income ranged from about $32,000 to $104,000 and the age groups were defined 
as 0-19, 20-34, 35-49, 50-64 and 65+(Non-Part D active or retired). RESULTS: The 
overall growth in average days’ supply of prescription medications varied 
considerably by income and age. Utilization growth was 1% or less for the top 
two income deciles and 2.3% and 6.6% for the bottom two deciles respectively in 
2011 and 2012. However, utilization for patients under age 35 increased as 
income increased (34.3% days in 2012). For patients 35 and older utilization 
decreased as income increased (-7.3% days in 2012). CONCLUSIONS: These 
results reinforce that for middle aged and older patients, lower income may be 
correlated with poorer health habits that may cause chronic disease. This is 
consistent with other published research indicating that health status is 
positively correlated with income.  
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OBJECTIVES: This study compares the fill patterns among patients with and 
without 90-day prescriptions at a national retail pharmacy chain. Specifically, 
the objective of this study is to determine whether 90-day supplies of Proton-
Pump Inhibitors (PPI) and Statins are associated with higher rates of patients 
changing from single source brand (SSB) medications to generic alternatives, and 
to determine the cost implications to patients and their benefit plans. 
METHODS: This retrospective cohort study includes a random sample of patients 
with 1 or more fills for SSB PPIs (N=96,927) or Statins (N=26,057) at Walgreens 
pharmacy in the first quarter of 2011. Study patients are assigned to the 90-day 
group, if they had a 90-day fill of PPI or Statin within 270 days of their index fill 
of SSB PPI or Statin, otherwise they are assigned to the 30-day group.The primary 
outcome measure is the change rate (CR) from SSB to generic medications within 
3 fills of the index date. RESULTS: The 90-day group has a significantly higher CR 
than the 30-day group: 9.3% versus 5.8% for PPI (p<0.0001) and 10.3% versus 7.5% 
for Statin (p value<0.0001). Co-pay savings per drug change were considerably 
higher for the 90-day group than the 30-day group ($46 vs. $30 for PPI and $39 vs. 
$27 for Statin); plan savings per drug change were also higher for the 90-day 
group ($259 vs. $121 for PPI and $164 vs. $83 for Statin). CONCLUSIONS: 
Compared with the 30-day group, patients in the 90-day group were observed to 
have a significantly higher rate of change from SSB drugs for generic drugs in 
both the PPI and Statin therapeutic classes. These physician approved 
medication changes translate into significant savings for both patients and their 
benefit plans.  
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OBJECTIVES: To examine determinants of drug therapy problems (DTPs) among 
home health patients receiving telephonic medication therapy management 
(MTM). METHODS: Retrospective data were used from patients (n=418) who 
participated in a randomized, controlled trial of telephonic MTM in a home 
health population. Data were extracted from two databases: 1) home health 
records from in-home nursing assessments (OASIS-C), and 2) MTM records from 
pharmacists’ telephonic assessments. The primary dependent variable was the 
number of DTPs identified by the pharmacist during the initial MTM encounter. 
Secondary dependent variables were the presence of subgroups of DTPs, 
including safety, effectiveness, indication, and adherence. Univariate and 
multivariate linear and logistic regression models assessed the relationship 
between DTPs and the independent variables: age, sex, race, functional status 
(cognitive, vision, hearing impairment and limited verbal understanding), 
hospitalization risk score, number of medications, Beers medications, narrow 
therapeutic index medications, self-reported adherence, and history of impaired 
medication management. RESULTS: Hospitalization risk score, Beers 
medications, hearing impairment, vision impairment, number of medications, 
